Indraprastha Medical Corporation growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+9.3%+9.0%+13.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+9.3%+26.3%+28.3%
+11.7%+30.4%+37.6%
+14.1%+29.9%+43.9%
+14.1%+29.9%+43.8%
+16.4%+17.8%+30.3%
+24.1%+24.9%+25.9%
+6.8%−21.7%+38.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INDRAMEDCO₹318.30

Indraprastha Medical Corporation Limited

· Pharma & Health
₹ CrorePeersARTEMISMEDSHALBYGKSLGPTHEALTHLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹2,918 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+13.3+9.0+9.3—
EBITDA Growth—+28.3+26.3+9.3—
EBIT Growth—+37.6+30.4+11.7—
Net Income Growth—+43.9+29.9+14.1—
EPS Growth—+43.8+29.9+14.1—
Total Assets Growth—+30.3+17.8+16.4—
Total Equity Growth—+25.9+24.9+24.1—
Cash from Operations Growth—+38.5-21.7+6.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.